Nurix Therapeutics, Inc. Common stock
$25.10
$0.27 (+1.09%)
$24.81Day Range$25.29
Key Statistics
Market Cap
$2.58B
Shares Outstanding
103.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 24, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$24.87
Day High
$25.29
Day Low
$24.81
Volume
554.2K
VWAP
$25.08
Prev Close
$24.83
Transactions
--
Acc. Volume
--
About Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
PHARMACEUTICAL PREPARATIONSSIC 2834357 employees1600 SIERRA POINT PKWY, BRISBANE, CA, 94005(415) 660-5320IPO Jul 24, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001549595
- Composite FIGI
- BBG00SDJ8M78
- Share Class FIGI
- BBG00SDJ8M87
- Ticker Root
- NRIX
- SIC Code
- 2834
About Nurix Therapeutics, Inc. Common stock (NRIX) Stock
Nurix Therapeutics, Inc. Common stock (NRIX) closed the 2026-09-16 session at $25.10, up 1.09% versus the previous close (+0.27). The stock opened at $24.87 and traded between $24.81 and $25.29 during that session. Session trading volume was 554K shares. The volume-weighted average price (VWAP) is $25.08.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Nurix Therapeutics, Inc. Common stock has a market capitalization of $2.58 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. NRIX is listed on the XNAS exchange. The company employs approximately 357 people. Nurix Therapeutics, Inc. Common stock is headquartered in BRISBANE, CA. The recorded listing date is 2020-07-24.
On this page you can find market NRIX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.